<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytopenias are typical of patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disease</z:e> (CTD) and are usually related to autoimmune phenomena </plain></SENT>
<SENT sid="1" pm="."><plain>In some cases, cytopenia may be the result of treatment with cytotoxic agents </plain></SENT>
<SENT sid="2" pm="."><plain>Although multi-drug therapy is known to produce <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in patients with CTD, treatment with single-agent therapy, particularly <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, has rarely been associated with <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Blood and marrow samples were studied from 3 men and 5 women with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo> (5 cases), <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> (2 cases), and <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (1 case) developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (5 cases), <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> (2 cases), and cytoxan (1 case) </plain></SENT>
<SENT sid="4" pm="."><plain>The durations of CTD ranged from less than 6 months to more than 10 years </plain></SENT>
<SENT sid="5" pm="."><plain>Five patients (63%) presented with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> including <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), refractory <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (RT), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with RT, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Of six patients presenting with or developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, four had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with differentiation (<z:e sem="disease" ids="C0026999" disease_type="Neoplastic Process" abbrv="">FAB M2</z:e>), one <z:hpo ids='HP_0004820'>acute myelomonocytic leukemia</z:hpo> (<z:e sem="disease" ids="C0023479" disease_type="Neoplastic Process" abbrv="AMML">FAB M4</z:e>), and one M4Eo </plain></SENT>
<SENT sid="8" pm="."><plain>Inv 16 was seen in the M4Eo and t(8;21) in one case of M2 </plain></SENT>
<SENT sid="9" pm="."><plain>Four of six patients are alive up to 6 years after diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>One of three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is alive 6 months after diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Cytopenias in patients with CTD may be due to <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> occurring in a setting of single-agent chemotherapy, including <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
</text></document>